Written By: Pharmacally Medical News Desk
Johnson & Johnson has reported results from the Phase 2b DUPLEX-AD proof-of-concept study (95475939ADM2001), which evaluated the investigational drug JNJ-95475939 (also known as JNJ-5939) for moderate to severe atopic dermatitis. A planned interim analysis triggered an early stop to the trial after the data failed to reach the high efficacy benchmarks the company had set for advancing the program.
Although the study did not achieve its predefined goals, JNJ-5939 was generally well tolerated, providing useful safety insights for future research. The company emphasized that the interim decision reflected rigorous development standards intended to prioritize only therapies with clear potential to deliver strong, meaningful benefit to patients.
In summary, while JNJ-5939 will not move forward based on the DUPLEX-AD findings, Johnson & Johnson continues to invest in research programs aimed at delivering new treatment choices for people living with atopic dermatitis. The experience gained from this study is expected to inform ongoing and future development efforts within the company’s dermatology portfolio.
References
Johnson & Johnson Statement on the Phase 2b DUPLEX-AD Study, 26 December 2025, https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-the-phase-2b-duplex-ad-study